Coagulation Factor IX
EstablishedFactor IX deficiency causes Hemophilia B; treatment options have expanded dramatically since 2024.
Factor IX deficiency causes Hemophilia B, a bleeding disorder. Treatment has changed enormously in the last two years, with new gene therapies and non-factor drugs approved in rapid succession — though one approved gene therapy was later pulled from the market for business reasons, a reminder that approval doesn't guarantee it stays available.
Factor IX is a vitamin K-dependent clotting protein; its deficiency causes Hemophilia B, an X-linked bleeding disorder. Treatment of Hemophilia B has undergone dramatic change in recent years.
Low Factor IX activity confirms Hemophilia B diagnosis and severity classification (severe <1%, moderate 1-5%, mild >5-40% activity), guiding both bleeding risk assessment and treatment planning.
Measured via specific factor IX clotting assay; genetic testing of the F9 gene can confirm diagnosis and inform family counseling given the X-linked inheritance pattern.
Treatment has evolved rapidly: two gene therapies reached FDA approval (one, Beqvez, approved April 2024 but discontinued by its manufacturer in February 2025 for commercial reasons), alongside new non-factor therapies — marstacimab (October 2024), concizumab (December 2024, expanded July 2025), and fitusiran (March 2025) — all reaching approval within roughly a 12-month span. Gene therapy approval does not guarantee lasting market availability, as the Beqvez withdrawal demonstrates.
Multiple new gene therapies and non-factor drugs approved 2024-2025, though not all remain commercially available.
- FDA. (2024). Summary Basis for Regulatory Action: BEQVEZ.
- CGTlive. (2026). Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez.